“Promomed”: the first Russian drug for the treatment of COVID-19 Areplivir passed registration registration in Russia. It is called Areplivir and will be admitted to hospitals by the end of 2021. This is reported by TASS with reference to the statement of the developer company Promomed.
The first domestic direct-acting intravenous antiviral drug Areplivir (favipiravir) received a registration certificate and will be admitted to hospitals in all regions by the end of the year. With its development, Promomed Group of Companies responded to the urgent need of domestic health care in hospital COVID-19 therapy
Areplivir promoted development company When deliveries begin
According to Promomed, full-fledged production at Biochemist JSC and deliveries to Russian hospitals will begin in December 2021.
2021 Areplivir will arrive in December to Russian hospitals
It is noted that a multicenter clinical trial of the drug led by Academician of the Russian Academy of Sciences Dmitry Pushkar confirmed the effectiveness and safety of the drug when used in hospitals.
Earlier, Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology, said that Russia is developing a drug to suppress the multiplication of coronavirus infection.
He also reported on the work on creating a drug from antibodies to treat patients with COVID-19. Clinical trials of the drug for patients with coronavirus will begin in January and will be completed within three to four months.
In addition, earlier in November it became known that Russia had created its own drug for coronavirus – innoviron, the developer of the drug was Valenta Pharm. Experts conducted the second phase of drug testing back in June. At the end of October this year, documents were sent to register the development.
Release formRelated materials10: 30 – October 19 
Antiviral express: 10 Moscow schools now have the opportunity to test for COVID-1917: 08 – 28 October 
Another COVID-19 attack in the Russian Federation seriously complicated
The company “Promomed” was the first in the world to create an injectable form of farapiravir, despite the fact that the powder does not dissolve in water. Injections will be recommended as a more effective form of treatment for patients in hospitals.
Also developed “Areplivir” for oral administration, it is included in the current recommendations both for treatment at home under the supervision of doctors, and in hospitals. The final decision will be made by the Russian Ministry of Health when revising methodological recommendations on coronavirus.
Evaluation of effectiveness
The chief pulmonologist of the Ministry of Health, Corresponding Member of the Russian Academy of Sciences Sergei Avdeev noted that until now the only drug to be administered as an injection was a foreign agent, not only expensive, but also inaccessible. He emphasized that the emergence of an effective domestic antiviral agent in the form of injections, which will become widely available, could reverse the course of the fight against the coronavirus pandemic.
The injectable form of the drug is characterized not only by one hundred percent bioavailability, but also by more intense penetration and distribution in cells , longer retention of therapeutic concentration in tissues, and an improved safety profile. This should significantly increase the effectiveness of treatment at the hospital stage
Sergey Avdeev Chief Pulmonologist of the Ministry of Health, Corresponding Member of the Russian Academy of Sciences
Previously head Federal Biomedical Agency (FMBA) Veronika Skvortsova said that the drug against coronavirus Mir-19 is completing the second phase of clinical trials. She recalled that Mir-19 belongs to the group of etiotropic antiviral drugs. It is intended to prevent or treat COVID-19 through inhalation or intranasal administration.